ALRN has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Aileron Therapeutics from a buy rating to a hold rating in a research report on Monday, July 8th. William Blair reiterated an outperform rating on shares of Aileron Therapeutics in a research note on Monday, May 6th. Finally, Canaccord Genuity dropped their target price on shares of Aileron Therapeutics to $5.00 and set a buy rating on the stock in a research note on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aileron Therapeutics presently has a consensus rating of Buy and an average price target of $4.33.
ALRN stock traded down $0.02 during trading on Thursday, reaching $0.55. The stock had a trading volume of 129,007 shares, compared to its average volume of 361,798. Aileron Therapeutics has a one year low of $0.44 and a one year high of $4.10. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.11 and a current ratio of 3.11. The stock has a 50 day moving average price of $0.67.
A hedge fund recently raised its stake in Aileron Therapeutics stock. Jennison Associates LLC raised its stake in Aileron Therapeutics Inc (NASDAQ:ALRN) by 649.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,040,255 shares of the company’s stock after acquiring an additional 1,768,073 shares during the quarter. Jennison Associates LLC owned approximately 13.72% of Aileron Therapeutics worth $3,828,000 as of its most recent filing with the Securities & Exchange Commission. 29.17% of the stock is owned by institutional investors.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Recommended Story: Google Finance Portfolio Tips and Tricks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.